Leading mid-market private equity firm LDC has made an £18m minority investment in TMC Pharma Services.
TMC Pharma Services (TMC) is a global pharmaceutical development organisation that specialises in innovative treatments for rare diseases and oncology. TMC has successfully supported over 150 Orphan Drug Designations in the past 10 years; in the USA, EU, Japan and Australia. The business provides a full range of expert pharma and biotech support services, from pre-clinical to post-marketing, for human medicines and devices. TMC’s senior team, based in the UK, is supported by a worldwide network of over 900 contracted Associates, who are hand-picked to match the exact needs of each individual project. TMC’s network of Associates includes some of the very best subject-matter experts in medicinal product development.
Target – TMC PHARMA SERVICES LIMITED
Buyer – LDC (MANAGERS) LIMITED
Seller – Shareholders
